JP2010522184A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522184A5 JP2010522184A5 JP2009554633A JP2009554633A JP2010522184A5 JP 2010522184 A5 JP2010522184 A5 JP 2010522184A5 JP 2009554633 A JP2009554633 A JP 2009554633A JP 2009554633 A JP2009554633 A JP 2009554633A JP 2010522184 A5 JP2010522184 A5 JP 2010522184A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- aryl
- alkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
- 208000012661 Dyskinesia Diseases 0.000 claims description 2
- 206010016212 Familial tremor Diseases 0.000 claims description 2
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 201000006517 essential tremor Diseases 0.000 claims description 2
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims description 2
- 230000001969 hypertrophic effect Effects 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 229920000155 polyglutamine Polymers 0.000 claims description 2
- 108010040003 polyglutamine Proteins 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 230000001148 spastic effect Effects 0.000 claims description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 17
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 150000002431 hydrogen Chemical group 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical group 0.000 claims 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 9
- -1 amino, hydroxy Chemical group 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000002252 acyl group Chemical group 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 229910004013 NO 2 Inorganic materials 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- 125000001931 aliphatic group Chemical group 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000005017 substituted alkenyl group Chemical class 0.000 claims 4
- 125000004426 substituted alkynyl group Chemical class 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010044074 Torticollis Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000003154 papilloma Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89592107P | 2007-03-20 | 2007-03-20 | |
| US60/895,921 | 2007-03-20 | ||
| US1528807P | 2007-12-20 | 2007-12-20 | |
| US61/015,288 | 2007-12-20 | ||
| PCT/US2008/056396 WO2008115719A1 (en) | 2007-03-20 | 2008-03-10 | Fused amino pyridine as hsp90 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010522184A JP2010522184A (ja) | 2010-07-01 |
| JP2010522184A5 true JP2010522184A5 (enExample) | 2011-04-28 |
| JP5401329B2 JP5401329B2 (ja) | 2014-01-29 |
Family
ID=39766345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554633A Active JP5401329B2 (ja) | 2007-03-20 | 2008-03-10 | Ｈｓｐ９０インヒビターとしての縮合アミノピリジン |
Country Status (24)
| Country | Link |
|---|---|
| US (10) | US8324240B2 (enExample) |
| EP (1) | EP2069324B1 (enExample) |
| JP (1) | JP5401329B2 (enExample) |
| KR (1) | KR101313804B1 (enExample) |
| CN (1) | CN101679347B (enExample) |
| AU (1) | AU2008229216B2 (enExample) |
| BR (1) | BRPI0808301B1 (enExample) |
| CA (1) | CA2680778C (enExample) |
| CY (1) | CY1114507T1 (enExample) |
| DK (1) | DK2069324T3 (enExample) |
| EA (1) | EA019103B1 (enExample) |
| ES (1) | ES2430217T3 (enExample) |
| HR (1) | HRP20130910T1 (enExample) |
| IL (2) | IL200924A (enExample) |
| MX (1) | MX2009009936A (enExample) |
| MY (1) | MY148860A (enExample) |
| NZ (1) | NZ579635A (enExample) |
| PL (1) | PL2069324T3 (enExample) |
| PT (1) | PT2069324E (enExample) |
| RS (1) | RS52978B (enExample) |
| SI (1) | SI2069324T1 (enExample) |
| TW (1) | TWI471131B (enExample) |
| WO (1) | WO2008115719A1 (enExample) |
| ZA (1) | ZA200906371B (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070129334A1 (en) * | 2001-10-30 | 2007-06-07 | Conforma Therapeutics Corporation | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 |
| US7834181B2 (en) * | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| CA2656202C (en) * | 2006-06-30 | 2018-01-16 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibition of hsp90 |
| KR20090077914A (ko) * | 2006-09-11 | 2009-07-16 | 쿠리스 인코퍼레이션 | 항증식제로서의 다작용성 소분자 |
| US20080234297A1 (en) * | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
| CN101679347B (zh) * | 2007-03-20 | 2014-10-22 | 柯瑞斯公司 | 作为hsp90抑制剂的稠和的氨基吡啶 |
| EP2088500A1 (en) | 2008-02-11 | 2009-08-12 | Idean Enterprises Oy | Layer based user interface |
| US8017780B1 (en) | 2008-10-09 | 2011-09-13 | Myrexis, Inc. | Therapeutic compounds and uses thereof |
| EP2387316A4 (en) | 2009-01-16 | 2012-06-13 | Curis Inc | CONDENSED AMINOPYRIDINE FOR THE TREATMENT OF BRAIN TUMORS |
| BRPI1013999B1 (pt) * | 2009-07-10 | 2020-06-02 | Taiho Pharmaceutical Co., Ltd. | Composto de azabiciclo e um sal deste, produto farmacêutico e composição farmacêutica compreendendo dito composto e uso do mesmo para tratar câncer |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| AU2013204109B2 (en) * | 2009-10-07 | 2016-05-05 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| DK2486039T3 (en) * | 2009-10-07 | 2016-09-12 | Sloan Kettering Inst For Cancer Res | Purine derivatives that are useful as HSP90 INHIBITORS |
| WO2011109448A1 (en) * | 2010-03-05 | 2011-09-09 | Baylor Research Institute | Involvement of androgen/androgen receptor pathway in fabry disease |
| WO2012131413A1 (en) | 2011-03-25 | 2012-10-04 | Debiopharm Sa | Crystalline forms of fused amino pyridines as hsp90 inhibitors |
| AU2012240079B2 (en) * | 2011-04-05 | 2017-05-18 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| WO2012138894A1 (en) * | 2011-04-05 | 2012-10-11 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| CA2833420C (en) * | 2011-04-26 | 2019-09-03 | Rdd Pharma Ltd. | Oxymetazoline for the treatment of ano-rectal disorders |
| SI3656758T1 (sl) | 2012-02-09 | 2024-06-28 | The University Of Kansas | Intermediati za pripravo c-terminalnih inhibitorjev hsp90 |
| BR112014029301A2 (pt) | 2012-05-25 | 2017-07-25 | Berg Llc | métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta |
| EP2972394A4 (en) | 2013-03-15 | 2016-11-02 | Sloan Kettering Inst Cancer | HSP90-DESIGNING AND THERAPY |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| WO2015023976A2 (en) | 2013-08-16 | 2015-02-19 | Memorial Sloan-Kettering Cancer Center | Selective grp94 inhibitors and uses thereof |
| US9994573B2 (en) | 2013-12-23 | 2018-06-12 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
| US10023864B2 (en) | 2014-06-06 | 2018-07-17 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| EP4494702A3 (en) | 2014-06-24 | 2025-02-26 | The University of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| BR112017005313A2 (pt) | 2014-09-17 | 2017-12-05 | Memorial Sloan Kettering Cancer Center | formação de imagem e terapia para inflamação e infecção direcionadas por hsp90 |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| HRP20211864T1 (hr) | 2015-07-06 | 2022-03-04 | Alkermes, Inc. | Inhibitori hetero-halo histonske deacetilaze |
| KR102526032B1 (ko) | 2017-01-11 | 2023-04-25 | 로딘 테라퓨틱스, 인크. | 히스톤 데아세틸라제의 바이시클릭 억제제 |
| HUE045261T2 (hu) | 2017-03-20 | 2019-12-30 | Forma Therapeutics Inc | Pirrolopirrol kompozíciók piruvát kináz (PKR) aktivátorokként |
| WO2018178767A1 (en) * | 2017-03-31 | 2018-10-04 | Alma Bio Therapeutics | Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same |
| SI3664802T1 (sl) | 2017-08-07 | 2022-10-28 | Alkermes, Inc. | Biciklični zaviralci histon deacetilaze |
| BR112020023277A2 (pt) | 2018-05-14 | 2021-02-23 | Reata Pharmaceuticals, Inc. | biaril amidas com grupos açúcar modificados para tratamento de doenças associadas à trajetória da proteína de choque térmico |
| US12122778B2 (en) | 2018-09-19 | 2024-10-22 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CN113166060B (zh) | 2018-09-19 | 2024-01-09 | 诺沃挪第克健康护理股份公司 | 用丙酮酸激酶激活化合物治疗镰状细胞病 |
| WO2020160151A1 (en) | 2019-01-31 | 2020-08-06 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitors |
| ES3042390T3 (en) | 2019-09-19 | 2025-11-20 | Novo Nordisk Healthcare Ag | Pyruvate kinase r (pkr) activating compositions |
| GB202006382D0 (en) | 2020-04-30 | 2020-06-17 | Spermatech As | Use |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| WO2023006993A1 (en) | 2021-07-30 | 2023-02-02 | Atmosr | Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome |
| AU2023356671A1 (en) * | 2022-10-06 | 2025-04-24 | Regranion, Llc | Methods and compositions for treating hidradenitis suppurativa |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025014551A1 (en) * | 2023-07-10 | 2025-01-16 | Regranion, Llc | Methods and compositions for treating atopic dermatitis |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080645A1 (en) * | 2023-10-10 | 2025-04-17 | Regranion, Llc | Methods and compositions for treating bullous pemphigoid |
| WO2025080629A1 (en) * | 2023-10-10 | 2025-04-17 | Regranion, Llc | Methods and compositions for treating behçet's disease |
| WO2025080623A1 (en) * | 2023-10-10 | 2025-04-17 | Regranion, Llc | Methods and compositions for treating discoid lupus erythematosus, systemic lupus erythematosus, and subacute cutaneous lupus erythematosus |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217284A1 (en) * | 2024-04-09 | 2025-10-16 | Regranion, Llc | Methods and compositions for treating inflammatory and autoimmune disorders of the skin |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ288182B6 (en) * | 1993-07-15 | 2001-05-16 | Minnesota Mining & Mfg | Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon |
| US5644063A (en) * | 1994-09-08 | 1997-07-01 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]pyridin-4-amine intermediates |
| US6723727B1 (en) * | 1996-12-20 | 2004-04-20 | Hoechst Aktiengesellschaft | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them |
| HUP0101810A3 (en) * | 1998-01-27 | 2002-05-28 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl factor xa inhibitors and pharmaceutical compositions containing them |
| EP1058549A4 (en) * | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | FACTOR Xa OR THROMBIN INHIBITORS |
| DE60022366T2 (de) * | 1999-07-02 | 2006-06-14 | Eisai Co Ltd | Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus |
| JP4829449B2 (ja) * | 1999-07-28 | 2011-12-07 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 置換オキソアザヘテロシクリル化合物 |
| US20020045613A1 (en) * | 2000-04-27 | 2002-04-18 | Heinz Pauls | 1-aroyl-piperidinyl benzamidines |
| JP2005519848A (ja) * | 2000-11-02 | 2005-07-07 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｈｓｐ９０に結合するための小分子組成物 |
| ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
| AU2002343604C1 (en) | 2001-10-30 | 2009-09-17 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
| US7160885B2 (en) * | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
| US7375228B2 (en) * | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20060148805A1 (en) * | 2003-07-01 | 2006-07-06 | Meng Hsin Chen | Opthalmic compositions for treating ocular hypertension |
| US7138401B2 (en) * | 2003-09-18 | 2006-11-21 | Conforma Therapeutics Corporation | 2-aminopurine analogs having HSP90-inhibiting activity |
| JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Ｍｓｄ株式会社 | 新規ピペリジン誘導体 |
| US20080015184A1 (en) * | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
| US20070259881A1 (en) * | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
| WO2006029115A2 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1h imidazo ring systems and methods |
| GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| US7834181B2 (en) * | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| WO2006114180A1 (de) * | 2005-04-25 | 2006-11-02 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
| US20070105874A1 (en) * | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
| WO2007075572A2 (en) * | 2005-12-22 | 2007-07-05 | Conforma Therapeutics Corporation | Orally active purine-based inhibitors of heat shock protein 90 |
| EP2012791A4 (en) * | 2006-02-07 | 2010-09-22 | Conforma Therapeutics Corp | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGUES AS INHIBITORS OF HSP90 |
| EP1987030B1 (en) | 2006-02-17 | 2011-11-09 | Pfizer Limited | 3 -deazapurine derivatives as tlr7 modulators |
| CN101490052B (zh) * | 2006-05-12 | 2012-08-08 | 美瑞德生物工程公司 | 治疗性化合物及其在癌症中的用途 |
| CA2656202C (en) | 2006-06-30 | 2018-01-16 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibition of hsp90 |
| KR20090077914A (ko) * | 2006-09-11 | 2009-07-16 | 쿠리스 인코퍼레이션 | 항증식제로서의 다작용성 소분자 |
| US8399452B2 (en) | 2006-10-28 | 2013-03-19 | Methylgene Inc. | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors |
| CN101679347B (zh) * | 2007-03-20 | 2014-10-22 | 柯瑞斯公司 | 作为hsp90抑制剂的稠和的氨基吡啶 |
| US20080234297A1 (en) * | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
| EP2387316A4 (en) | 2009-01-16 | 2012-06-13 | Curis Inc | CONDENSED AMINOPYRIDINE FOR THE TREATMENT OF BRAIN TUMORS |
-
2008
- 2008-03-10 CN CN200880016525.7A patent/CN101679347B/zh active Active
- 2008-03-10 MY MYPI20093837A patent/MY148860A/en unknown
- 2008-03-10 WO PCT/US2008/056396 patent/WO2008115719A1/en not_active Ceased
- 2008-03-10 KR KR1020097021910A patent/KR101313804B1/ko active Active
- 2008-03-10 JP JP2009554633A patent/JP5401329B2/ja active Active
- 2008-03-10 NZ NZ579635A patent/NZ579635A/en unknown
- 2008-03-10 BR BRPI0808301-0A patent/BRPI0808301B1/pt active IP Right Grant
- 2008-03-10 US US12/045,509 patent/US8324240B2/en active Active
- 2008-03-10 PT PT87437554T patent/PT2069324E/pt unknown
- 2008-03-10 SI SI200831049T patent/SI2069324T1/sl unknown
- 2008-03-10 EP EP08743755.4A patent/EP2069324B1/en active Active
- 2008-03-10 HR HRP20130910AT patent/HRP20130910T1/hr unknown
- 2008-03-10 AU AU2008229216A patent/AU2008229216B2/en active Active
- 2008-03-10 CA CA2680778A patent/CA2680778C/en active Active
- 2008-03-10 PL PL08743755T patent/PL2069324T3/pl unknown
- 2008-03-10 EA EA200901263A patent/EA019103B1/ru unknown
- 2008-03-10 MX MX2009009936A patent/MX2009009936A/es active IP Right Grant
- 2008-03-10 DK DK08743755.4T patent/DK2069324T3/da active
- 2008-03-10 ES ES08743755T patent/ES2430217T3/es active Active
- 2008-03-10 RS RS20130434A patent/RS52978B/sr unknown
- 2008-03-13 TW TW97108801A patent/TWI471131B/zh active
-
2009
- 2009-09-14 ZA ZA200906371A patent/ZA200906371B/xx unknown
- 2009-09-14 IL IL200924A patent/IL200924A/en active IP Right Grant
-
2012
- 2012-03-20 US US13/424,780 patent/US8586605B2/en active Active
-
2013
- 2013-10-15 US US14/054,273 patent/US9040556B2/en active Active
- 2013-10-17 CY CY20131100916T patent/CY1114507T1/el unknown
-
2015
- 2015-01-26 IL IL236938A patent/IL236938A0/en unknown
- 2015-04-08 US US14/681,310 patent/US9402832B2/en active Active
-
2016
- 2016-07-01 US US15/200,232 patent/US9630965B2/en active Active
-
2017
- 2017-03-30 US US15/474,248 patent/US10035797B2/en active Active
-
2018
- 2018-07-11 US US16/032,282 patent/US10428068B2/en active Active
-
2019
- 2019-08-28 US US16/553,764 patent/US10844056B2/en active Active
-
2020
- 2020-10-29 US US17/083,964 patent/US11560377B2/en active Active
-
2022
- 2022-12-15 US US18/081,966 patent/US20230192687A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010522184A5 (enExample) | ||
| JP2013536833A5 (enExample) | ||
| MX2018005215A (es) | Derivados de n-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-p iperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para el tratamiento de enfermedades neurologicas. | |
| JP2012515724A5 (enExample) | ||
| NZ603896A (en) | 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia | |
| CA2495386A1 (en) | Protein kinase inhibitors and uses thereof | |
| FI3215511T3 (fi) | Substituoituja pyratsolo(1,5-a)pyrimidiinejä ja niiden käyttö lääketieteellisten häiriöiden hoitamisessa | |
| JP2017537948A5 (enExample) | ||
| JP2013010792A5 (enExample) | ||
| JP2009504748A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| WO2006105063A1 (en) | Heterobicylic inhibitors of tgfbeta | |
| JP2019510787A5 (enExample) | ||
| JP2009526830A5 (enExample) | ||
| JP2020527588A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2013500314A5 (enExample) | ||
| JP2013533879A5 (enExample) | ||
| JP2012532137A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| MX348920B (es) | Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
| JP2009535307A5 (enExample) | ||
| JP2010526867A5 (enExample) |